ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Surface contamination with SARS-CoV-2: A systematic review.The Science of the total environment · 2021Pooled it
- Severe Respiratory Illness and Death Associated with Outbreak of Human Rhinovirus B14 among Older Adults, France, 2024.Emerging infectious diseases · 2026Article
- Exploring novel kinetics of automated HMicrobiology spectrum · 2026Article
- Convergent Evolution and Host-Limiting Impacts of SARS-CoV-2 Revealed by Cellular Experiments.Molecular biology and evolution · 2025Article
- Discontinuous template switching generates coronavirus subgenomic RNAs from the 3' viral genome end by 5' to 3' transcription.Journal of virology · 2025Article
- Article
- The inactivation of the Niemann Pick C1 cholesterol transporter restricts SARS-CoV-2 entry into host cells by decreasing ACE2 abundance at the plasma membrane.Cell & bioscience · 2024Article
- Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications.mSphere · 2024Article
- Tirofiban prevents the effects of SARS-CoV-2 spike protein on macrophage activation and endothelial cell death.Heliyon · 2024Article
- Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.ACS omega · 2024Review
- Evaluation of the PrimeFlow RNA assay as a method of detection of SARS-CoV-2 single and dual Infections.Cytotechnology · 2024Article
- Timing and Predictors of Loss of Infectivity Among Healthcare Workers With Mild Primary and Recurrent COVID-19: A Prospective Observational Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Observational
- Features of SARS-CoV-2 Replication in Various Types of Reptilian and Fish Cell Cultures.Viruses · 2023Article
- Postbiotic Preparation ofAntioxidants (Basel, Switzerland) · 2023Article
- Emerging Landscape of Preclinical Models for Studying COVID-19 Neurologic Diseases.ACS pharmacology & translational science · 2023Review
- Congenital SARS-CoV-2 Infection in Two Neonates with Confirmation by Viral Culture of the Placenta in One Case.Viruses · 2023Article
- Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus.iScience · 2023Article
- Updated analysis to reject the laboratory-engineering hypothesis of SARS-CoV-2.Environmental research · 2023Article
- SARS-CoV-2 infection of thymus induces loss of function that correlates with disease severity.The Journal of allergy and clinical immunology · 2023Article
- Analysis of the Virus SARS-CoV-2 as a Potential Bioweapon in Light of International Literature.Military medicine · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The emergence of COVID-19 disease due to SARS-CoV-2 at the end of 2019 was rapidly associated with the isolation of the strain from co-culture onto VERO cells. These isolations quickly made it possible to carry out the first tests for antiviral agents' susceptibility and drug repurposing. However, it seems important to make an inventory of all the cells that can support the growth of this virus and evaluate possible differences between isolates. In the present work, we tested 4 strains of SARS-CoV-2 locally isolated on a panel of 34 cell lines present in our laboratory and commonly used for the isolation of human pathogenic microorganism. After inoculation, cells were observed for cytopathic effects and quantitative real-time polymerase reaction was used to measure the virus replication on the cells. We were able to obtain growth on 7 cell lines, 6 simian, and the human Caco-2. The cytopathogenic effects are variable, ranging from lysis of the cell monolayer in 48-72 h to no cytopathic effect in spite of intense multiplication, as in Caco-2 cells. Interestingly, effect and multiplication varied widely according to the strain tested. In this paper, we explored the species specificity and tissue tropism of SARS-CoV-2 in vitro on a panel of cells available in our laboratory and identified human and animal cell lines susceptible to support SARS-CoV-2 replication. Our work highlights the importance of testing multiple strains when testing antiviral molecules and performing patho-physiological analyzes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.